-
What The Depo-Provera Meningioma Warning Added In 2025 Means For New Depo-Provera Lawsuits In 2026
Women Who Had Depo-Provera Injections Before December 2025 Label Change Can Still Sue Responsible Pharmaceutical Drug Companies (Posted by Tom Lamb at Drug Injury Watch) In December 2025, a Depo-Provera “meningioma warning” label change was required by…
-
Rybelsus Deep Vein Thrombosis Case Report: Medical Journal, 2026
Rybelsus (Semaglutide) Associated With Significantly Increased Risk Of Blood Clots (Posted by Tom Lamb at Drug Injury Watch) In this post, we point out a recent medical journal article that discusses a Rybelsus deep vein thrombosis case…
-
NAION Eye Side Effect for Ozempic and Mounjaro: Drug Injury Lawsuits Update January 2026
Federal Court MDL: IN RE: Glucagon-like Peptide-1 Receptor Agonists (GLP-1 RAs) Non-Arteritic Anterior Ischemic Optic Neuropathy Products Liability Litigation (Posted by Tom Lamb at Drug Injury Watch) In December 2025, the U.S. Judicial Panel on Multidistrict Litigation…
-
Wegovy and Ozempic Patients Get Compensation for NAION Vision Loss In Europe
Because Semaglutide is Linked to NAION, Wegovy and Ozempic Drug Injury Cases Have Been Filed In the US (Posted by Tom Lamb at Drug Injury Watch) For more than a year now, we have been looking into…
-
Depo-Provera Meningioma Cases: Women With At Least 4 Years Use or Starting Injections After Age 31
Higher Risk Of Meningioma Side Effects Associated With Depo-Provera for These Women, According to a 2025 Medical Study Report (Posted by Tom Lamb at Drug Injury Watch) A recent medical study looking at Depo-Provera meningioma cases in…
